Patents by Inventor Judith A. James
Judith A. James has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240120053Abstract: Disclosed herein are methods of treating neuropsychiatric and cognitive conditions in individuals by titrating a 5-HT receptor agonist over a period of time to provide a therapeutic effective amount of the 5-HT receptor agonist to the individual.Type: ApplicationFiled: September 6, 2023Publication date: April 11, 2024Inventors: Judith BLUMSTOCK, William James TYLER, Jeffrey SPROUSE
-
Publication number: 20240011983Abstract: A method for determining whether a Systemic lupus erythematosus (SLE) patient is undergoing a pre-flare event, the method comprising obtaining a blood, serum, plasma, or saliva sample from the SLE patient; assessing a level of expression for each of a plurality of biomarkers, the plurality of biomarkers comprising OPN, MCP-1/CCL2, MCP-3/CCL7, IL-17A, TNFRII, TNFRI, IL-4, IL-5, BLyS, TNF?, and IL-7; determining a Lupus Flare Risk Prediction Index (LFPI) for the patient based upon the level of expression for each of a plurality of biomarkers; and based upon the LFPI, determining whether the patient is undergoing a pre-flare event.Type: ApplicationFiled: July 21, 2021Publication date: January 11, 2024Applicants: Progentec Diagnostics, Inc., Oklahoma Medical Research FoundationInventors: Melissa MUNROE, Judith JAMES, Eldon JUPE, Mohan PURUSHOTHAMAN
-
Publication number: 20230266315Abstract: The present invention involves the identification of biomarkers that are predictive of impeding systemic lupus erythematosus (SLE) disease flare. Methods for treating patients so identified are also provided.Type: ApplicationFiled: September 16, 2022Publication date: August 24, 2023Applicants: Oklahoma Medical Research Foundation, Oklahoma Medical Research FoundationInventors: Judith A. James, Melissa E. Munroe
-
Patent number: 11585810Abstract: The present invention involves the identification of biomarkers that are predictive of impeding systemic lupus erythematosus (SLE) disease flare. Methods for treating patients so identified are also provided.Type: GrantFiled: July 15, 2019Date of Patent: February 21, 2023Assignee: OKLAHOMA MEDICAL RESEARCH FOUNDATIONInventors: Judith A. James, Melissa E. Munroe
-
Publication number: 20210396751Abstract: A method for characterizing disease activity in a systemic lupus erythematosus patient (SLE), comprising obtaining a dataset associated with a blood, serum, plasma or urine sample from the patient, assessing the dataset for a presence or an amount of protein expression of at least one innate serum or plasma mediator, assessing the dataset for a presence or an amount of protein expression of at least one adaptive serum or plasma mediator biomarker, assessing the dataset for a presence or an amount of at least one chemokine/adhesion molecule biomarker, assessing the dataset for a presence or an amount of at least one soluble TNF superfamily biomarker, assessing the dataset for a presence or an amount of at least one inflammatory mediator biomarker, assessing the dataset for a presence or an amount at least one SLE-associated autoantibody specificity biomarker and calculating a Lupus Disease Activity Immune Index (LDAII) score.Type: ApplicationFiled: August 25, 2021Publication date: December 23, 2021Inventors: Melissa MUNROE, Judith JAMES, Eldon JUPE, Mohan PURUSHOTHAMAN
-
Publication number: 20200049705Abstract: The present invention involves the identification of biomarkers that are predictive of impeding systemic lupus erythematosus (SLE) disease flare. Methods for treating patients so identified are also provided.Type: ApplicationFiled: July 15, 2019Publication date: February 13, 2020Inventors: Judith A. James, Melissa E. Munroe
-
Publication number: 20190390278Abstract: The present invention involves the identification of biomarkers that are predictive of impeding systemic lupus erythematosus (SLE) disease flare. Methods for treating patients so identified are also provided.Type: ApplicationFiled: January 25, 2018Publication date: December 26, 2019Inventors: Judith A. James, Melissa E. Munroe
-
Patent number: 10393739Abstract: The present invention involves the identification of biomarkers that are predictive of impeding systemic lupus erythematosus (SLE) disease flare. Methods for treating patients so identified are also provided.Type: GrantFiled: August 11, 2016Date of Patent: August 27, 2019Assignee: Oklahoma Medical Research FoundationInventors: Judith A. James, Melissa E. Munroe
-
Publication number: 20160349256Abstract: The present invention involves the identification of biomarkers that are predictive of impeding systemic lupus erythematosus (SLE) disease flare. Methods for treating patients so identified are also provided.Type: ApplicationFiled: August 11, 2016Publication date: December 1, 2016Inventors: Judith A. James, Melissa E. Munroe
-
Publication number: 20150098940Abstract: The present invention involves the identification of biomarkers that are predictive of impeding systemic lupus erythematosus (SLE) disease flare. Methods for treating patients so identified are also provided.Type: ApplicationFiled: October 2, 2014Publication date: April 9, 2015Applicant: OKLAHOMA MEDICAL RESEARCH FOUNDATIONInventors: Judith A. James, Melissa E. Munroe
-
Publication number: 20110110954Abstract: Compositions and methods effective for eliciting an immune response for preventing or reducing infection or improving clinical outcomes caused by Bacillus anthracis are provided. The compositions include a naturally occurring or synthetic protein, peptide, or protein fragment containing all or an active portion of an antigenic epitope associated with anthrax toxin proteins optionally combined with a pharmaceutically acceptable carrier. The preferred antigenic epitopes correspond to immunogenic regions of protective antigen, lethal factor or edema factor, either individually or in combination. In addition, methods and compositions containing antibodies for reducing the effects of anthrax toxins are described. The methods involve administering to a human or animal the compositions described herein in a dosage sufficient to elicit an immune response or treat the anthrax infection.Type: ApplicationFiled: September 13, 2010Publication date: May 12, 2011Applicant: Oklahoma Medical Research FoundationInventors: Judith A. James, Darise Farris, Sherry Crowe
-
Patent number: 7888458Abstract: Data consistent with autoimmune disease being caused by Epstein-Barr virus are shown. Based on this evidence, an effective vaccine would prevent the autoimmune disease in those vaccinated, modified or administered so that the vaccine is not itself capable of inducing autoimmune disease. In the case of anti-Sm, structures to be avoided in an Epstein-Barr virus-derived vaccine have been identified. Differences have been identified in the immune responses to Epstein-Barr infection between individuals who develop a specific autoimmune disease and those who do not. These differences are used to distinguish those who are at greater risk for developing specific autoimmune diseases from those who are a lesser risk. Assuming Epstein-Barr virus causes autoimmune disease and that Epstein-Barr virus remains latent in the patient for life, reactivation of the virus from the latent state is important in generating or maintaining the autoimmune response that culminates in autoimmune disease.Type: GrantFiled: January 13, 1997Date of Patent: February 15, 2011Inventors: John B. Harley, Judith A. James
-
Patent number: 7794732Abstract: Compositions and methods effective for eliciting an immune response for preventing or reducing infection or improving clinical outcomes caused by Bacillus anthracis are provided. The compositions include a naturally occurring or synthetic protein, peptide, or protein fragment containing all or an active portion of an antigenic epitope associated with anthrax toxin proteins optionally combined with a pharmaceutically acceptable carrier. The preferred antigenic epitopes correspond to immunogenic regions of protective antigen, lethal factor or edema factor, either individually or in combination. In addition, methods and compositions containing antibodies for reducing the effects of anthrax toxins are described. The methods involve administering to a human or animal the compositions described herein in a dosage sufficient to elicit an immune response or treat the anthrax infection.Type: GrantFiled: May 14, 2007Date of Patent: September 14, 2010Assignee: Oklahoma Medical Research FoundationInventors: Judith A. James, Darise Farris, Sherry Crowe
-
Publication number: 20100172926Abstract: Compositions and methods effective for eliciting an immune response for preventing or reducing infection or improving clinical outcomes caused by Bacillus anthracis are provided. The compositions include a naturally occurring or synthetic protein, peptide, or protein fragment containing all or an active portion of an antigenic epitope associated with anthrax toxin proteins optionally combined with a pharmaceutically acceptable carrier. The preferred antigenic epitopes correspond to immunogenic regions of protective antigen, lethal factor or edema factor, either individually or in combination. In addition, methods and compositions containing antibodies for reducing the effects of anthrax toxins are described. The methods involve administering to a human or animal the compositions described herein in a dosage sufficient to elicit an immune response or treat the anthrax infection.Type: ApplicationFiled: May 14, 2007Publication date: July 8, 2010Applicant: OKLAHOMA MEDICAL RESEARCH FOUNDATIONInventors: Judith A. James, Darise Farris, Sherry Crowe
-
Patent number: 7276341Abstract: A number of octapeptides were generated from the sequences encoding the 60 kDa Ro/SSA peptide, the La/SSB autoantigen, the 70 kD nuclear ribonucleoprotein (nRNP), and the Sm B/B? polypeptide, which represent linear epitopes for autoantibodies present in the sera of SLE and SS patients. These peptides are useful in solid phase assays for patients characterized by the presence of these autoantibodies, and can be used to categorize patients as to the likelihood of developing certain conditions associated with SLE. The peptides are also potentially useful in treatment of these patients using immobilized peptide to remove autoantibody and to block binding of the autoantibodies with patient molecules reactive with the autoantibodies.Type: GrantFiled: February 27, 2003Date of Patent: October 2, 2007Assignee: Oklahoma Medical Research FoundationInventors: John B. Harley, Judith A. James
-
Patent number: 7273613Abstract: Data consistent with autoimmune disease being caused by Epstein-Barr virus are shown. Based on this evidence, an effective vaccine would prevent the autoimmune disease in those vaccinated, modified or administered so that the vaccine is not itself capable of inducing autoimmune disease. In the case of anti-Sm, structures to be avoided in an Epstein-Barr virus-derived vaccine have been identified. Differences have been identified in the immune responses to Epstein-Barr infection between individuals who develop a specific autoimmune disease and those who do not. These differences are used to distinguish those who are at greater risk for developing specific autoimmune diseases from those who are a lesser risk. Assuming Epstein-Barr virus causes autoimmune disease and that Epstein-Barr virus remains latent in the patient for life, reactivation of the virus from the latent state is important in generating or maintaining the autoimmune response that culminates in autoimmune disease.Type: GrantFiled: February 9, 2000Date of Patent: September 25, 2007Assignees: The Board of Regents, The University of Oklahoma, Oklahoma Medical Research FoundationInventors: John B. Harley, Judith A. James, Kenneth M. Kaufman
-
Patent number: 7192715Abstract: Data consistent with autoimmune disease being caused by Epstein-Barr virus are shown. Based on this evidence, an effective vaccine would prevent the autoimmune disease in those vaccinated, modified or administered so that the vaccine is not itself capable of inducing autoimmune disease. In the case of anti-Sm, structures to be avoided in an Epstein-Barr virus-derived vaccine have been identified. Differences have been identified in the immune responses to Epstein-Barr infection between individuals who develop a specific autoimmune disease and those who do not. These differences are used to distinguish those who are at greater risk for developing specific autoimmune diseases from those who are a lesser risk. Assuming Epstein-Barr virus causes autoimmune disease and that Epstein-Barr virus remains latent in the patient for life, reactivation of the virus from the latent state is important in generating or maintaining the autoimmune response that culminates in autoimmune disease.Type: GrantFiled: October 24, 2001Date of Patent: March 20, 2007Assignee: Oklahoma Medical Research FoundationInventors: John B. Harley, Judith A. James
-
Publication number: 20060257427Abstract: Compositions that bind viral proteins that are specifically expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells that harbor latent virus. In a preferred embodiment the compositions are antibodies which bind the extracellular region of the latent viral protein, most preferably LMP-2A, an EBV latent protein, which are conjugated to a diagnostic or cytotoxic agent or immobilized to a solid support for removal of the infected cells. These antibodies are capable of distinguishing cells expressing EBV DNA from cells which are not expressing EBV DNA. Compositions that can be used to elicit production of these antibodies, or as a vaccine, are also disclosed. Methods for generating diagnostic or cytotoxic reagents and vaccines based on the viral epitopes that identify cells harboring latent virus are also disclosed.Type: ApplicationFiled: April 17, 2006Publication date: November 16, 2006Inventors: John Harley, Judith James, Kenneth Kaufman
-
Publication number: 20060257428Abstract: Compositions that bind viral proteins that are specifically expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells that harbor latent virus. In a preferred embodiment the compositions are antibodies which bind the extracellular region of the latent viral protein, most preferably LMP-2A, an EBV latent protein, which are conjugated to a diagnostic or cytotoxic agent or immobilized to a solid support for removal of the infected cells. These antibodies are capable of distinguishing cells expressing EBV DNA from cells which are not expressing EBV DNA. Compositions that can be used to elicit production of these antibodies, or as a vaccine, are also disclosed. Methods for generating diagnostic or cytotoxic reagents and vaccines based on the viral epitopes that identify cells harboring latent virus are also disclosed.Type: ApplicationFiled: April 17, 2006Publication date: November 16, 2006Inventors: John Harley, Judith James, Kenneth Kaufman
-
Patent number: 7078173Abstract: Compositions that bind viral proteins that are specifically expressed during the latent stage of the viral life cycle are disclosed. These compositions bind the latent viral proteins while the viral proteins are expressed in their cellular host, and provide a means for targeting cells that harbor latent virus. In a preferred embodiment the compositions are antibodies which bind the extracellular region of the latent viral protein, most preferably LMP-2A, an EBV latent protein, which are conjugated to a diagnostic or cytotoxic agent or immobilized to a solid support for removal of the infected cells. These antibodies are capable of distinguishing cells expressing EBV DNA from cells which are not expressing EBV DNA. Compositions that can be used to elicit production of these antibodies, or as a vaccine, are also disclosed. Methods for generating diagnostic or cytotoxic reagents and vaccines based on the viral epitopes that identify cells harboring latent virus are also disclosed.Type: GrantFiled: August 22, 2003Date of Patent: July 18, 2006Assignee: Oklahoma Medical Research FoundationInventors: John B. Harley, Judith A. James, Kenneth M. Kaufman